ADHERING TROCHES WITH SANTACID FOR TREATMENT OF THROAT ESOPHAGUS AND STOMACH

• US 20100285098A1
• Filed: 09/10/2008
• Published: 11/11/2010
• Est. Priority Date: 09/11/2007
• Status: Abandoned Application

• Current Assignee: Jeffrey T. Haley
• Original Assignee: Jeffrey T. Haley
• Inventors: Haley, Jeffrey T.
• Application Number:
  US12/735,017
• Publication Number:
  US 20100285098A1
• Time in Patent Office: Days
• US Class Current: 424/435
• CPC Class Codes: A61K 36/484 Glycyrrhiza (licorice)
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28

Abstract

A method for combating unwanted conditions downstream of the mouth with adhering troches. A method to treat or reduce replication of a virus in throat tissues by releasing an anti-viral from an adhering disc. A method to treat sore throat with time release of Glycyrrhiza extract or collagen from an adhering disc. A method to treat sore throat with topically applied cobalamin. An adhering troche that releases antacid, alginate, bismuth subsalicylate, soluble zinc, such as zinc gluconate, bioactive vitamin B12 (methylcobalamin), antibiotic, or anti-viral. A method to combat bacterial effects downstream of the mouth with topically applied xylitol.

Claims

1-14. -14. (canceled)

15. An adhering troche, at least 5 mm in each of at least two dimensions, with a slow rate of dissolution in saliva comprising at least 200 mg of antacid compounds.

16. The troche of claim 15 wherein, when exposed to saliva in a human mouth, the dissolution time of the troche is more than 25 minutes at typical mid day levels of saliva flow.

17. The troche of claim 15 wherein the antacid compounds comprise at least one of:

sodium bicarbonate, calcium bicarbonate, magnesium bicarbonate, aluminum bicarbonate, calcium carbonate, magnesium carbonate, aluminum carbonate, sodium carbonate, magnesium trisilicate, alumina, magnesium oxide, magnesium hydroxide, and aluminum hydroxide.

32. The troche of claim 15 comprising two layers, a first adhesive layer of 30 to 99% adhesive gums that adheres in a human mouth and a second delivery layer that contains the antacid compounds.)

33. The troche of claim 32 wherein the second delivery layer that contains the antacid compounds comprises at least 75% antacid compounds.)

18-31. -31. (canceled)

33-1. The troche of claim 32 having a total thickness of about 4 to 5 millimeters.